258 related articles for article (PubMed ID: 12493173)
1. Synergy of colistin with rifampin and trimethoprim/sulfamethoxazole on multidrug-resistant Stenotrophomonas maltophilia.
Giamarellos-Bourboulis EJ; Karnesis L; Giamarellou H
Diagn Microbiol Infect Dis; 2002 Nov; 44(3):259-63. PubMed ID: 12493173
[TBL] [Abstract][Full Text] [Related]
2. In vitro synergy of colistin combinations against colistin-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae isolates.
Vidaillac C; Benichou L; Duval RE
Antimicrob Agents Chemother; 2012 Sep; 56(9):4856-61. PubMed ID: 22751540
[TBL] [Abstract][Full Text] [Related]
3. Detection of multidrug resistant environmental isolates of
Govender R; Amoah ID; Kumari S; Bux F; Stenström TA
J Environ Sci Health A Tox Hazard Subst Environ Eng; 2021; 56(2):213-225. PubMed ID: 33378222
[No Abstract] [Full Text] [Related]
4. Risk factors and molecular mechanisms associated with trimethoprim-sulfamethoxazole resistance in Stenotrophomonas maltophilia in Mexico.
Herrera-Heredia SA; Pezina-Cantú C; Garza-González E; Bocanegra-Ibarias P; Mendoza-Olazarán S; Morfín-Otero R; Camacho-Ortiz A; Villarreal-Treviño L; Rodríguez-Noriega E; Paláu-Davila L; Maldonado-Garza HJ; Flores-Treviño S
J Med Microbiol; 2017 Aug; 66(8):1102-1109. PubMed ID: 28771141
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Trimethoprim/Sulfamethoxazole (SXT), Minocycline, Tigecycline, Moxifloxacin, and Ceftazidime Alone and in Combinations for SXT-Susceptible and SXT-Resistant Stenotrophomonas maltophilia by In Vitro Time-Kill Experiments.
Wei C; Ni W; Cai X; Zhao J; Cui J
PLoS One; 2016; 11(3):e0152132. PubMed ID: 26999818
[TBL] [Abstract][Full Text] [Related]
6. Effect of antimicrobials on
Santos Carvalhais BE; Souza E Silva C; Dos Santos KV
Future Microbiol; 2021 Jan; 16(2):83-93. PubMed ID: 33470844
[No Abstract] [Full Text] [Related]
7. Activity of Potential Alternative Treatment Agents for Stenotrophomonas maltophilia Isolates Nonsusceptible to Levofloxacin and/or Trimethoprim-Sulfamethoxazole.
Biagi M; Tan X; Wu T; Jurkovic M; Vialichka A; Meyer K; Mendes RE; Wenzler E
J Clin Microbiol; 2020 Jan; 58(2):. PubMed ID: 31748318
[No Abstract] [Full Text] [Related]
8. Levofloxacin-resistant Stenotrophomonas maltophilia: risk factors and antibiotic susceptibility patterns in hospitalized patients.
Wang CH; Yu CM; Hsu ST; Wu RX
J Hosp Infect; 2020 Jan; 104(1):46-52. PubMed ID: 31505224
[TBL] [Abstract][Full Text] [Related]
9. Interactions of colistin and rifampin on multidrug-resistant Acinetobacter baumannii.
Giamarellos-Bourboulis EJ; Xirouchaki E; Giamarellou H
Diagn Microbiol Infect Dis; 2001 Jul; 40(3):117-20. PubMed ID: 11502379
[TBL] [Abstract][Full Text] [Related]
10. In Vitro Bactericidal Activity of Trimethoprim-Sulfamethoxazole Alone and in Combination with Colistin against Carbapenem-Resistant Acinetobacter baumannii Clinical Isolates.
Nepka M; Perivolioti E; Kraniotaki E; Politi L; Tsakris A; Pournaras S
Antimicrob Agents Chemother; 2016 Nov; 60(11):6903-6906. PubMed ID: 27550356
[TBL] [Abstract][Full Text] [Related]
11. Antibiotic susceptibility of sulfamethoxazole-trimethoprim resistant Stenotrophomonas maltophilia strains isolated at a tertiary care centre in Hungary.
Juhász E; Pongrácz J; Iván M; Kristóf K
Acta Microbiol Immunol Hung; 2015 Sep; 62(3):295-305. PubMed ID: 26551572
[TBL] [Abstract][Full Text] [Related]
12.
Flamm RK; Shortridge D; Castanheira M; Sader HS; Pfaller MA
Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31427295
[TBL] [Abstract][Full Text] [Related]
13. Temperature, pH and Trimethoprim-Sulfamethoxazole Are Potent Inhibitors of Biofilm Formation by Stenotrophomonas maltophilia Clinical Isolates.
Biočanin M; Madi H; Vasiljević Z; Kojić M; Jovčić B; Lozo J
Pol J Microbiol; 2017 Dec; 66(4):433-438. PubMed ID: 29319523
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial susceptibility and combination testing of invasive Stenotrophomonas maltophilia isolates.
Church D; Lloyd T; Peirano G; Pitout J
Scand J Infect Dis; 2013 Apr; 45(4):265-70. PubMed ID: 23113657
[TBL] [Abstract][Full Text] [Related]
15. In vitro killing effect of moxifloxacin on clinical isolates of Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole.
Giamarellos-Bourboulis EJ; Karnesis L; Galani I; Giamarellou H
Antimicrob Agents Chemother; 2002 Dec; 46(12):3997-9. PubMed ID: 12435710
[TBL] [Abstract][Full Text] [Related]
16. Class 1 integrons increase trimethoprim-sulfamethoxazole MICs against epidemiologically unrelated Stenotrophomonas maltophilia isolates.
Barbolla R; Catalano M; Orman BE; Famiglietti A; Vay C; Smayevsky J; Centrón D; Piñeiro SA
Antimicrob Agents Chemother; 2004 Feb; 48(2):666-9. PubMed ID: 14742234
[TBL] [Abstract][Full Text] [Related]
17. The sul1 gene in Stenotrophomonas maltophilia with high-level resistance to trimethoprim/sulfamethoxazole.
Chung HS; Kim K; Hong SS; Hong SG; Lee K; Chong Y
Ann Lab Med; 2015 Mar; 35(2):246-9. PubMed ID: 25729729
[TBL] [Abstract][Full Text] [Related]
18. In vitro combination of tigecycline with other antibiotics in Stenotrophomonas maltophilia isolates.
Karamanlıoğlu D; Dizbay M
Turk J Med Sci; 2019 Apr; 49(2):683-686. PubMed ID: 30866602
[TBL] [Abstract][Full Text] [Related]
19. In Vitro Bactericidal Activity of Trimethoprim-Sulfamethoxazole/Colistin Combination Against Carbapenem-Resistant Klebsiella pneumoniae Clinical Isolates.
Su J; Li D; Guo Q; Guo Y; Zheng Y; Xu X
Microb Drug Resist; 2019 Mar; 25(2):152-156. PubMed ID: 30109975
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for hospital acquisition of trimethoprim-sulfamethoxazole resistant Stenotrophomonas maltophilia in adults: A matched case-control study.
Wang CH; Lin JC; Chang FY; Yu CM; Lin WS; Yeh KM
J Microbiol Immunol Infect; 2017 Oct; 50(5):646-652. PubMed ID: 28688829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
